Sciensus

Looking forward to an inspiring Exchange during WODC in Amsterdam #sciensus #WODC

Looking forward to WODC Europe DM if you are interested in talking about introducing your product into Europe from pre approval early access to full commercialisation #sciensus #WODCEurope #orphan medicines #partnership

One of the things we’ve learned through our work with NHS homecare teams is that digital transformation doesn’t always need to mean introducing something radically new. Often, the bigger opportunity is removing the friction that has built up around an existing process. Prescription renewals are a good example. There can still be a number of manual steps involved, from creating and signing a prescription through to clinical checking, scanning, emailing or posting it to the homecare provider. None is particularly complex on its own, but together they can create delays and make it difficult for teams to see where a prescription is in the process. That’s what we’ve addressed with e-prescribing through the Sciensus Connect Portal. We’ve developed it in partnership and around the way NHS teams already work, rather than asking hospitals to redesign their processes around our technology. Since launching in July, four hospitals have submitted 556 prescriptions through the pathway. 35% have reached Sciensus within one day. It’s early, and there is plenty still to learn. But for me, this is where digital technology can make a practical difference: making an important part of the homecare pathway simpler, more visible and easier to manage. More on what we’re learning in our latest blog: https://lnkd.in/evUM-VRp

We are looking forward to being part of the World Orphan Drug Congress (WODC) in Amsterdam in less than two weeks! Get in touch if you are interested to discuss our established and integrated distributor model to provide sustainable access to orphan or complex medicines; including GMP labelling, distribution, tendering, patient support programmes, clinical homecare and real world data collection. #sciensus #wodceurope2026 #orphanmedicines

At Sciensus we offer a range of options to help bring your rare disease therapy to patients across Europe. Whether you are looking to enter the market through an Early Access Programme or Named Patient Supply Programme, need commercialisation support or require import, QP, GDP/GMP, specialty distribution, clinical home care or real-world evidence services, Sciensus can create a customised plan to meet the specific needs of your therapy across Europe. Book a meeting directly using the link below to discuss how we could support your plans: https://lnkd.in/gdNbVp9m #RareDisease #Biotech #Pharmaceuticals #Europe #Commercialisation #EAP #NPP #SpecialtyDistribution #HomeCare #RWE

We've been working on something new at Sciensus: extending our clinical homecare model to self-funded private care. Plenty of patients don't get NICE approval for a therapy their consultant believes is right for them, and self-funding becomes the only route. The problem I keep hearing from smaller and independent practices is that writing the prescription is the easy part. Sourcing the medicine, coordinating payment, arranging delivery and supporting the patient at home is where it gets hard, especially without an in-house pharmacy. We're piloting a service that takes that on: onboarding, payment coordination, medicine delivery and home-based clinical support through our specialist nurse network, while the consultant stays in charge of the treatment plan. Starting with the specialties where self-funding is most common: dermatology, respiratory, neurology, rheumatology and allergy. We're registering practices now. If this sounds like something your patients could use, I'd welcome a conversation, drop me a message. More detail on the thinking behind it here: https://lnkd.in/dFv3cxNj #sciensus #homecare #privatehealthcare #selfpay #dermatology #rheumatology #gastroenterology #respiratory #neurology #allergy